Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Merz Pharma

X
Drug Profile

Botulinum toxin A - Merz Pharma

Alternative Names: Bocouture; Incobotulinum toxin A; NT 201L; NT-201; Xeomeen; XEOMIN; Xeomin; Xeomin cosmetic; Zeomaine

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIOTECON Therapeutics
  • Developer Merz Aesthetics; Merz Pharma; Merz Pharmaceuticals GmbH; Yale University
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Sialorrhoea; Torticollis
  • Phase III Atrial fibrillation; Facial wrinkles
  • Phase II Alopecia; Essential tremor; Pain; Skin aging; Trigeminal neuralgia
  • Phase I Unspecified
  • Discontinued Cancer pain

Most Recent Events

  • 24 Jan 2024 Merz Aesthetics completes the phase-II PAOLA trial in Skin aging (Platysma Prominence) in USA (IM) (NCT05773053)
  • 22 Nov 2023 Launched for Sialorrhoea (In children, In adults) in Australia (IM)
  • 21 Nov 2023 Registered for Sialorrhoea (In adults, In children) in Australia (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top